NIAID will host a virtual workshop entitled “Mucosal Vaccines for SARS-CoV-2: Scientific Gaps and Opportunities” on November 7-8 2022 from 10-4 EST. The workshop will explore the state of the [...]
“Launched in September 2021, the Influenza Vaccines Roadmap provides a global framework for guiding R&D activities aimed at developing improved seasonal influenza vaccines and [...]
US National Institute of Allergy and Infectious Diseases (NIAID) Notice of Special Interest (NOSI)—Advancing Research Needed To Develop a Universal Influenza Vaccine: the purpose of the funding [...]
The Universal Influenza Vaccine Technology Landscape is a database of novel vaccine candidates designed to provide broader and more durable immunity against circulating and pandemic influenza [...]
The Center for Infectious Disease Research and Policy (CIDRAP), with support from the Wellcome Trust, a London-based research nonprofit—with an eye toward improving flu vaccines, promoting truly [...]
Conventional influenza vaccines are designed to stimulate neutralizing antibodies against immunodominant but highly variable hemagglutinin antigens. Inherent limitations include suboptimal [...]
“As the number of people infected with the coronavirus (which causes the coronavirus disease 2019, or COVID-19) continues to rise, the full extent and severity of this outbreak still [...]
“An unwelcome visitor during the holiday season has returned: influenza. As of today, six children have already fallen victim to the disease. And, as the Centers for Disease Control and [...]
In response to global interest in the development of a universal influenza vaccine, the Bill & Melinda Gates Foundation, PATH, and the Global Funders Consortium for Universal Influenza [...]
In response to global interest in the development of a universal influenza vaccine, the Bill & Melinda Gates Foundation, PATH, and the Global Funders Consortium for Universal Influenza [...]
